Editor’s note: This post was updated on June 9 to include a statment from Pharmsource. People with diabetes who use the Dexcom G7 continuous glucose monitoring system need to check the lot numbers on ...

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use insulin.

DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom ...

DexCom Inc. DXCM stock is trading higher on Monday after the diabetes management company reported positive results from its ...

DexCom, Inc. (DXCM Quick Quote DXCM - Free Report) recently announced the FDA clearance for its 15-day wear G7 Continuous Glucose Monitoring (CGM) system, the longest-lasting and most accurate CGM ...

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its latest ...

DexCom Inc. DXCM recently announced that its G7 Continuous Glucose Monitoring (CGM) System will be added to the Régie de l'assurance maladie du Québec (RAMQ) Public Prescription Drug Insurance Plan.

Compare the best Samsung Watch CGM apps and Wear OS tools for blood sugar readings, including Dexcom G6, Gluroo, and xDrip+.

Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support.